Novartis buys neurology biotech Cadent for up to $770mNovartis is to buy neuroscience drugs firm Cadent Therapeutics in a deal worth up to $770 million. The Share XNovartis buys neurology biotech Cadent for up to $770mhttps://pharmaphorum.com/news/novartis-buys-neurology-biotech-cadent-for-up-to-770m/
VC fund dedicated to psychedelic meds launches in UKIn the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – Share XVC fund dedicated to psychedelic meds launches in UKhttps://pharmaphorum.com/news/vc-fund-dedicated-to-psychedelic-meds-launches-in-uk/
Biogen bulks up pipeline with Sage drugs in $3bn dealWith the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore Share XBiogen bulks up pipeline with Sage drugs in $3bn dealhttps://pharmaphorum.com/news/biogen-bulks-up-pipeline-with-sage-drugs-in-3bn-deal/
MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOCompass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy Share XMindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOhttps://pharmaphorum.com/news/mindmed-aims-for-nasdaq-listing-after-compass-magic-mushroom-fuelled-ipo/
Compass plans $100m IPO to fund magic mushroom depression drugUK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its Share XCompass plans $100m IPO to fund magic mushroom depression drughttps://pharmaphorum.com/news/compass-plans-100m-ipo-to-fund-magic-mushroom-depression-drug/
NICE rejects Janssen’s depression spray Spravato for second timeNICE has rejected regular NHS funding for Janssen’s depression spray Spravato (esketamine) for a second time, although the Share XNICE rejects Janssen’s depression spray Spravato for second timehttps://pharmaphorum.com/news/nice-rejects/
Digital depression therapy offers hope during COVID-19 pandemicA new digital therapy is aiming to tackle depression during the COVID-19 pandemic, using a brain stimulation headset Share XDigital depression therapy offers hope during COVID-19 pandemichttps://pharmaphorum.com/news/digital-depression-therapy-offers-hope-during-covid-19-pandemic/
Orexo buys US rights to GAIA’s deprexis digital therapeuticSweden’s Orexo has announced it has bought the exclusive US rights to GAIA’s deprexis, a digital therapy to Share XOrexo buys US rights to GAIA’s deprexis digital therapeutichttps://pharmaphorum.com/news/orexo-buys-us-rights-to-gaias-deprexis-digital-therapeutic/
ECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKThe top EU court has endorsed an earlier decision by the UK financial regulator to fine GlaxoSmithKline in Share XECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKhttps://pharmaphorum.com/news/ecj-backs-uk-regulators-pay-for-delay-fine-levied-on-gsk/